Fifteen of top 25 are drug or device makers; hospitals and distributors round out the list
Saying that, by identifying 25 top-performing firms in delivering value across a supply chain from manufacturer to patient in a healthcare setting, AMR Research hopes to raise the importance and recognition of good supply-chain practices throughout healthcare. The Boston market-analysis firm combined quantitative assessments of ROA and inventory turns with qualitative rankings by two panels: a group of outside experts, and the AMR analysts. The company plans to update the list annually while highlighting new, successful innovations.
The Healthcare Top 25 (ranked by their composite scoring):
1. Johnson & Johnson
2. Sisters of Mercy Health System
3. Cardinal Health
4. Owens & Minor
5. McKesson
6. CVS Caremark
7. Abbott Laboratories
8. Novartis
9. Becton Dickinson
10. Wyeth
11. GlaxoSmithKline
12. AstraZeneca
13. AmerisourceBergen
14. Walgreens
15. Covidien
16. Cleveland Clinic
17. Merck
18. Genentech
19. Alcon Laboratories
20. Medtronic
21. Boston Scientific
22. BJC Healthcare System
23. Roche
24. Amgen
25. Mayo Clinic
From a biopharma perspective, AMR’s scope is a little unfamiliar: The company defines the healthcare value chain from manufacturer to a patient, but mostly one in a hospital or clinical system—something that directly represents only about a quarter of the biopharma market. Some qualifiers: except for the healthcare systems, AMR limited its analysis to publicly traded firms, which would exclude, among others, privately held wholesalers like HD Smith; it did not include distributors that have large business outside of healthcare (which would have brought distribution companies like UPS Healthcare Logistics into consideration); and, according to AMR chief strategy officer Kevin O’Marah, “rightly or wrongly, we are biased against payers and other intermediaries” which thus excluded PBMs and mail-order pharmacies like Medco (even though the PBM parts of CVS Caremark or Walgreens got in via their retail operations).
Even so, the ranking is sure to generate discussion, at least among biopharma companies who compete head to head, and the longer-term goal, according to AMR VP Hussain Mooraj, is to highlight the efficiencies to be had by better collaboration among trading partners, better sales & operations planning, and a stronger patient focus.
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.